August 2016 in “Journal of Investigative Dermatology” Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.
May 2025 in “The Journal of Rheumatology” Anti-CD19 therapy may help treat SLE and NMOSD.
August 2009 in “Australian Prescriber” Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.
July 2024 in “Journal of Investigative Dermatology” A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.
July 2024 in “Journal of Investigative Dermatology” Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.
January 2025 in “Cell Communication and Signaling” CXXC5 can both suppress and promote cancer, making it a complex target for treatment.
1 citations
,
April 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Tislelizumab can cause cutaneous lupus erythematosus.
9 citations
,
May 2005 in “Expert Review of Clinical Immunology” Blocking interferon-gamma might help treat various autoimmune diseases.
October 2021 in “Journal of Investigative Dermatology” Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.
28 citations
,
September 2014 in “Journal of Veterinary Internal Medicine” VDC-1101 shows potential as a treatment for canine cutaneous T-cell lymphoma.
32 citations
,
June 2012 in “PLoS ONE” Blocking IL-8 can reduce skin rashes from cancer treatment.
October 2022 in “Amplla Editora eBooks” Tocilizumab might be an effective treatment for COVID-19.
107 citations
,
December 2003 in “Dermatologic Therapy” Interferon, especially alfa interferon, is an effective treatment for cutaneous T-cell lymphoma with manageable side effects.
September 2021 in “Journal of the American Academy of Dermatology” CTCL patients can safely continue treatment during COVID-19 with proper safety measures.
5 citations
,
June 2022 in “Frontiers in immunology” Increasing Treg cells in the skin does not cure hair loss from alopecia areata in mice.
1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
11 citations
,
September 1999 in “Journal of the European Academy of Dermatology and Venereology” Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.
10 citations
,
October 2016 in “Monoclonal antibodies in immunodiagnosis and immunotherapy” Researchers created specific antibodies that detect a protein important in development and various conditions, and can be used for research and diagnosis.
July 2023 in “British journal of dermatology/British journal of dermatology, Supplement” Skin tumors with CYLD cutaneous syndrome show more NF-κB activity and less organized collagen.
36 citations
,
March 2014 in “Annals of the Rheumatic Diseases” Activating liver X receptors can reduce fibrosis by stopping certain immune cells from releasing harmful proteins.
January 2019 in “International Journal of Immunology Research” CCL 27 levels are similar in people with and without alopecia areata.
25 citations
,
April 1985 in “Journal of Investigative Dermatology” 4 citations
,
September 2024 in “Cell Reports” Granulocyte colony stimulating factor helps heal wounds without scars.
May 2025 in “The Journal of Rheumatology” Early diagnosis and treatment are crucial for CAPS, and Eculizumab can be effective.
40 citations
,
December 2012 in “PLoS ONE” Removing Ctip2 in skin cells causes skin inflammation similar to atopic dermatitis.
89 citations
,
March 1996 in “Proceedings of the National Academy of Sciences” CD18-deficient mice developed psoriasis-like skin disease, useful for studying inflammatory skin disorders.
14 citations
,
May 2019 in “Human gene therapy” MC-DNA vector-based gene therapy can temporarily treat CBS deficiency in mice.
December 2021 in “Research Square (Research Square)” M-CSF-stimulated myeloid cells can cause alopecia areata in mice.
November 2025 in “The Journal of Immunology” A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.